A look back at May 2023 photos by Post
May 31, 2023What to Look For When Lifting Your GMC Truck
May 02, 20231 Quick And Surprising Tool To Boost Your Performance Under Work Stress
Jun 25, 2023AccuAir Launches New Dynamic Lift Kits for Jeep Wrangler JKU Models
Sep 07, 2023Ford Bronco Owners Say Trail Turn Assist Is Breaking Diffs
Oct 01, 2023Asco 2023
After Arcus/Gilead's Tigit shocker yesterday, Asco today brought another bombshell. Roche's fact-finding mid-stage Morpheus-liver trial, which had sent Tigit-fixated investors’ pulses racing a week ago, has delivered a strong enough signal for a phase 3 trial to be launched, Asco learned this afternoon.
Presenting the Morpheus-liver data in full, UCLA's Dr Richard Finn outlined a global, placebo-controlled study, Imbrave-152/Skyscraper-14, that would pit tiragolumab, Tecentriq plus Avastin versus a Tecentriq/Avastin doublet in the front-line setting. This, he told Asco, would measure overall and investigator-assessed progression-free survival as co-primary endpoints, and was "expected to begin soon".
His enthusiasm was backed not only by the topline PFS numbers generated by Morpheus-liver, but also by a retrospective analysis using "Bayesian dynamic borrowing" designed to generate possible "synthetic" control arms. The purpose of this was to counter one of the readout's biggest criticisms, namely that Morpheus-liver's actual control arm vastly underperformed the performance of Tecentriq plus Avastin in Roche's Imbrave-150 trial, flattering the result.
The new analysis aimed to counteract imbalances in patients’ baseline criteria, and generated three possible more realistic controls, ranging from a conservative to a fully matched scenario. Each generated a positive reduction in risk of progression or death, from 28% to 51% with tiragolumab, Tecentriq plus Avastin, versus a Tecentriq/Avastin doublet. Meanwhile, Morpheus-liver showed a 58% reduction.
Still, it is not entirely clear why the mid-stage trial's actual control cohort underperformed. The Asco presentation revealed patients’ baseline imbalances, some of which favoured active treatment, though others, including disease severity, favoured control. Moreover, Morpheus-liver overall contained a lower percentage of hepatitis B patients than Imbrave-150.
All these considerations aside, Finn said the fundamental confounding issue might have been Morpheus-liver's relatively small size. The study discussant, Memorial Sloan Kettering's Dr Ghassan Abou-Alfa, said that while Bayesian modelling was intriguing Morpheus-liver should simply be celebrated for delivering a positive result that now needed corroborating in a larger trial.
Investors in other Tigit companies – not least Arcus – might be celebrating tomorrow, too.
This story has been updated to include more information about the "synthetic" control arms generated by Roche.